Nuevocor to Present Pre-clinical Data on its Gene Therapy Candidate for LMNA Dilated Cardiomyopathy at American Heart Association Scientific Sessions 2022
- Written by PR Newswire
SINGAPORE, Oct. 28, 2022 /PRNewswire/ -- Nuevocor, a pre-clinical stage cardiac gene therapy company, announced today that it will present new preclinical data on its adeno-associated virus (AAV) gene therapy for LMNA dilated cardiomyopathy at the American Heart Association (AHA) Scientific Sessions meeting on 5 – 7 November, 2022. This...
Read more: Nuevocor to Present Pre-clinical Data on its Gene Therapy Candidate for LMNA Dilated...














